CAR T against cell surface proteins to treat prostate cancer

Researchers at University of California Los Angeles identified cell surface targets to treat prostate adenocarcinoma and neuroendocrine prostate cancer, two distinct major subtypes of advanced prostate cancer, and suggested that CAR T cell therapy against one of the targets could help treat neuroendocrine prostate cancer.

The study appeared in Proceedings of the National Academy of Sciences...